Reviva Pharmaceuticals (RVPH) News Today $0.98 -0.14 (-12.53%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Reviva to Participate in the UBS Global Healthcare ConferenceOctober 31 at 8:00 AM | globenewswire.comReviva to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 8, 2024 | globenewswire.comReviva to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comReviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor ConferenceSeptember 26, 2024 | markets.businessinsider.comReviva Pharmaceuticals Holdings, Inc. (RVPHW)September 12, 2024 | ca.finance.yahoo.comReviva Pharmaceuticals Holdings (RVPH) Earnings Dates & ReportsSeptember 12, 2024 | investing.comReviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaSeptember 9, 2024 | finanznachrichten.deReviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaSeptember 9, 2024 | markets.businessinsider.comRVPH Jan 2026 5.000 callSeptember 8, 2024 | ca.finance.yahoo.comReviva to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comRVPH: August OLE UpdateAugust 27, 2024 | msn.comExplainer-Big Tech wants AI to be regulated. Why do they oppose a California AI bill?August 21, 2024 | msn.comReviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq RulesAugust 21, 2024 | globenewswire.comMaxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH)August 17, 2024 | msn.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024August 14, 2024 | investorplace.comReviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary FibrosisAugust 6, 2024 | finance.yahoo.comReviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary HypertensionJuly 9, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 30, 2024 | prnewswire.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | finance.yahoo.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | globenewswire.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | finance.yahoo.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 23, 2024 | prnewswire.comRVPH: Enrollment Right Around the CornerMay 22, 2024 | finance.yahoo.comReviva to Participate in the BIO International ConventionMay 21, 2024 | globenewswire.comReviva Pharmaceuticals Holdings, Inc.May 20, 2024 | edition.cnn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 16, 2024 | prnewswire.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | finance.yahoo.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | globenewswire.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | investorplace.comReviva Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 14, 2024 | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceMay 13, 2024 | globenewswire.comRVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPHMay 10, 2024 | prnewswire.comReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual MeetingMay 9, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 6, 2024 | prnewswire.comReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHMay 4, 2024 | morningstar.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | stockhouse.comRVPH: Full Year 2023 ResultsApril 25, 2024 | finance.yahoo.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 25, 2024 | businesswire.comBrokers Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2024 EPS estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now eApril 24, 2024 | marketbeat.comHC Wainwright Weighs in on Reviva Pharmaceuticals Holdings, Inc.'s Q1 2025 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.33) per sApril 23, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 22, 2024 | markets.businessinsider.comReviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday.April 22, 2024 | marketbeat.comReviva Pharmaceuticals' (RVPH) "Speculative Buy" Rating Reiterated at BenchmarkBenchmark reissued a "speculative buy" rating and issued a $17.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday.April 16, 2024 | marketbeat.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataApril 15, 2024 | msn.comRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023April 15, 2024 | investorplace.comReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | finanznachrichten.deReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | globenewswire.com Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Bezos, & Congress Are Piling Into This One Sector (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… Click here for the details RVPH Media Mentions By Week RVPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVPH News Sentiment▼0.000.38▲Average Medical News Sentiment RVPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVPH Articles This Week▼11▲RVPH Articles Average Week Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MDWD News LFCR News VTYX News LFVN News HOWL News IPHA News GBIO News ACTU News CNTX News TNYA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
